We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s assets for $305 million. The transaction — which arrives more than three ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

TTAM Research Institute acquires 23andMe in a $305 million bankruptcy sale, transitioning the DNA testing giant to a ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.

The court-appointed Consumer Privacy Ombudsman (CPO) in the 23andMe bankruptcy last month released a 200-plus-page report ...

After Foley Hoag’s prior updates regarding the chapter 11 bankruptcy cases of 23andMe Holding Co and its affiliated debtors ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Former CEO Anne Wojcicki's nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe's assets for US$305 million.

Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...